



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Correspondence

Opsoclonus After COVID-19 in an Infant



Burr et al. report a toddler with autoimmune encephalitis following a COVID-19 infection.¹ We describe a child with another immune-mediated disorder in an infant after a SARS-CoV-2 infection.

This four-month-old female twin was admitted after developing episodic chaotic eye movement and tongue thrusting. Her symptoms began one month after a COVID-19 infection with brief, unheralded conjugate eye movements in all directions. She experienced up to eight episodes per day, the longest of which lasted seven minutes. The mother provided smartphone videos of two episodes and consented to share these images (Video). She tried to halt or reduce the episodes by placing her hand over the eyes. Her development had been normal with no evidence of regression.

Twin girls were born by Caesarean section at 36 weeks' gestation after normal prenatal care including a normal twentieth-week ultrasound. At age five weeks she was treated for cough and dyspnea and released from the emergency department, but screening nasal swabs for COVID-19 in both the twins and their mother were positive. The patient's respiratory symptoms cleared in less than a week, but then the mother observed "eye vibrations."

During her hospital admission, she was afebrile and interactive between episodes. Cranial nerves were intact. She had normal to mildly increased muscle tone, normal strength, reflexes, and coordination. Aside from the eye movements, her neurological and eye examinations were normal, with steady fixation, reactive pupils, moderate hyperopic astigmatism, and normal retinæ without papilledema or optic nerve pallor.

A prolonged video electroencephalography demonstrated no epileptiform discharges and captured an eight-minute episode of abnormal eye movement that was not epileptic in nature. Magnetic resonance imaging of the head and spine with and without contrast and computed tomography of chest, abdomen, and pelvis were negative. Cerebrospinal fluid tests for protein, glucose, and

oligoclonal bands were negative. Complete blood count, magnesium, phosphorus, C-reactive protein, carnitine, plasma amino acids, and paraneoplastic antibody panel were normal. Urine for homovanillic acid and vanillylmandelic acid were normal. Urine organic acids were normal and autoimmune encephalitis panel, anti-HU (Human neuron-specific RNA-binding protein HuD), and anti-N-methyl-D-aspartate receptor antibody were all negative. The repeat COVID-19 swab was negative, but her COVID-19 IgG/IgM antibody test was positive.

She was treated with intravenous immunoglobulin and corticosteroids with prompt elimination of the eye movements, then discharged on oral corticosteroids.

Opsoclonus or saccadomania is a chaotic eye movement disorder often associated with myoclonus. Etiologies include toxins, paraneoplastic syndromes, and postinfectious disorders.² The infant described here corroborates two earlier reports documenting opsoclonus following a COVID-19 infection in older patients.^{3,4}

Supplementary data

The video associated with this article can be found online at <https://doi.org/10.1016/j.pediatrneurol.2020.12.009>.

References

- Burr T, Barton C, Doll E, Lakhota A, Sweeney M. N-Methyl-D-Aspartate receptor encephalitis associated with COVID-19 infection in a toddler. *Pediatr Neurol*. 2020;114:75–76.
- Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("tumor" vs. "no tumor") in a cohort of 356 US children. *Pediatr Blood Cancer*. 2018;65:e27097.
- Shah PB, Desai SD. Opsoclonus myoclonus ataxia syndrome (OMAS) in the setting of COVID-19 infection. *Neurology*. 2021;96:33.
- Sanguinetti S, Ramdhani RA. Opsoclonus myoclonus ataxia syndrome related to the novel coronavirus (COVID-19). *J Neuroophthalmol*. 2020.

Conflicts of Interest/Financial Disclosure: No conflicts for any author related to this Case report.

For completeness: Dr. Arnold is President of Glacier Medical Software that makes cloud-based NICU monitoring ROP-Check and also President of PDI Check that makes a patent-pending vision screening game for the autostereoscopic Nintendo 3DS console. Dr. Arnold coordinates the Alaska Blind Child Discovery, which has received discounted vision screening technology from several vendors. Dr. Arnold is an investigator and protocol developer for the NIH-funded Pediatric Eye Disease Investigator Group.

Institutional Review Board: Pacific.

Clinical Trials Registry: n/a.

Data Access: n/a.

Contributor's Statement Page: All authors collected data, contributed to writing and critical review, and gave approval. Darion L. Heald, BS, MSIII, Irisa M Devine, MD, Roderic L. Smith, MD, PhD, Sarah A.T. Holsopple, MD, Jessica L. Aras-smith, MD, and Robert W. Arnold, MD, FAAP, collected data, drafted, and helped revise article; gave final approval to this version; and agreed to be accountable for all aspects of this work.

Darion L. Heald, MSIII

University of Washington School of Medicine, WWAMI, Anchorage, Alaska

Irisa M. Devine, MD, Roderic L. Smith, MD, PhD
Pediatric Neurology, Anchorage, Alaska

Sarah A.T. Holsopple, MD, Jessica L. Aras-smith, MD
Pediatric Specialists of Alaska, The Children's Hospital at Providence, Anchorage, Alaska

Robert W. Arnold, M.D.
Alaska Children's EYE & Strabismus, Anchorage, Alaska
E-mail address: eyedoc@alaska.net.

Available online 1 January 2021